On the public citation graph

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis

0 signed · 558 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2016.13512openalex-snapshot
Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug
inferredcites →https://doi.org/10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-ropenalex-snapshot
Preliminary definition of improvement in juvenile arthritis
inferredcites →https://doi.org/10.1002/1529-0131(199805)41:5<808::aid-art6>3.0.co;2-topenalex-snapshot
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
inferredcites →https://doi.org/10.1002/1529-0131(199902)12:1<52::aid-art9>3.0.co;2-xopenalex-snapshot
Effects of an eight-week physical conditioning program on disease signs and symptoms in children with chronic arthritis
inferredcites →https://doi.org/10.1002/1529-0131(200101)44:1<180::aid-anr24>3.0.co;2-kopenalex-snapshot
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug
inferredcites →https://doi.org/10.1002/acr.20283openalex-snapshot
Abatacept improves health‐related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/acr.20460openalex-snapshot
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features
inferredcites →https://doi.org/10.1002/acr.21697openalex-snapshot
Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: An observational study with patients from the German Methotrexate Registry
inferredcites →https://doi.org/10.1002/acr.21801openalex-snapshot
Disease activity and fatigue in juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/acr.21947openalex-snapshot
Delineating the Role of Multiple Intraarticular Corticosteroid Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era
inferredcites →https://doi.org/10.1002/acr.22087openalex-snapshot
2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications
inferredcites →https://doi.org/10.1002/acr.22393openalex-snapshot
Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three‐Variable Juvenile Arthritis Disease Activity Score
inferredcites →https://doi.org/10.1002/acr.22657openalex-snapshot
A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis
inferredcites →https://doi.org/10.1002/acr.23871openalex-snapshot
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
inferredcites →https://doi.org/10.1002/art.10444openalex-snapshot
Long‐term outcome in patients with juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.10710openalex-snapshot
Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial
inferredcites →https://doi.org/10.1002/art.10986openalex-snapshot
Daily pain and symptoms in children with polyarticular arthritis
inferredcites →https://doi.org/10.1002/art.1780400703openalex-snapshot
Preliminary definition of improvement in juvenile arthritis
inferredcites →https://doi.org/10.1002/art.20861openalex-snapshot
Long‐term open‐label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular‐course juvenile rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.20952openalex-snapshot
Pain, stiffness, and fatigue in juvenile polyarticular arthritis: Contemporaneous stressful events and mood as predictors
inferredcites →https://doi.org/10.1002/art.20985openalex-snapshot
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty‐two–week, randomized, controlled study
inferredcites →https://doi.org/10.1002/art.21778openalex-snapshot
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
inferredcites →https://doi.org/10.1002/art.22838openalex-snapshot
A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.23427openalex-snapshot
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.23916openalex-snapshot
Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.24477openalex-snapshot
Disease control and health‐related quality of life in juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.24516openalex-snapshot
Development and validation of a composite disease activity score for juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.24777openalex-snapshot
Long‐term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.27431openalex-snapshot
Long‐term safety and efficacy of abatacept in children with juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.30367openalex-snapshot
High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score
inferredcites →https://doi.org/10.1002/art.34343openalex-snapshot
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1002/art.34373openalex-snapshot
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score
inferredcites →https://doi.org/10.1002/art.34498openalex-snapshot
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial
inferredcites →https://doi.org/10.1002/art.38092openalex-snapshot
2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications
inferredcites →https://doi.org/10.1002/art.38741openalex-snapshot
Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry
inferredcites →https://doi.org/10.1002/art.39197openalex-snapshot
Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
inferredcites →https://doi.org/10.1002/art.39234openalex-snapshot
Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years
inferredcites →https://doi.org/10.1002/art.39298openalex-snapshot
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
inferredcites →https://doi.org/10.1002/art.39573openalex-snapshot
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
inferredcites →https://doi.org/10.1002/art.40350openalex-snapshot
Review: Genetics and the Classification of Arthritis in Adults and Children
inferredcites →https://doi.org/10.1007/s00296-009-0942-3openalex-snapshot
Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept
inferredcites →https://doi.org/10.1007/s10067-014-2744-6openalex-snapshot
Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis
inferredcites →https://doi.org/10.1007/s12325-017-0578-8openalex-snapshot
Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
inferredcites →https://doi.org/10.1016/j.clinthera.2017.06.009openalex-snapshot
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany
inferredcites →https://doi.org/10.1016/j.jclinepi.2010.09.012openalex-snapshot
GRADE guidelines: 2. Framing the question and deciding on important outcomes
inferredcites →https://doi.org/10.1016/j.jclinepi.2012.03.013openalex-snapshot
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
inferredcites →https://doi.org/10.1016/j.jclinepi.2013.02.003openalex-snapshot
GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength
inferredcites →https://doi.org/10.1016/s0140-6736(08)60998-8openalex-snapshot
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
inferredcites →https://doi.org/10.1038/ng.2614openalex-snapshot
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1056/nejm199204163261602openalex-snapshot
Methotrexate in Resistant Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejm200003163421103openalex-snapshot
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejmoa041810openalex-snapshot
Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejmoa0706290openalex-snapshot
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejmoa1303006openalex-snapshot
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
inferredcites →https://doi.org/10.1093/rheumatology/33.5.461openalex-snapshot
PAIN RELIEF IN THE RHEUMATOID KNEE AFTER STEROID INJECTION A SINGLE-BLIND COMPARISON OF HYDROCORTISONE SUCCINATE, AND TRIAMCINOLONE ACETONIDE OR HEXACETONIDE
inferredcites →https://doi.org/10.1093/rheumatology/38.3.235openalex-snapshot
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial
inferredcites →https://doi.org/10.1093/rheumatology/39.2.198openalex-snapshot
Juvenile chronic arthritis into adulthood: a long‐term follow‐up study
inferredcites →https://doi.org/10.1093/rheumatology/41.11.1330openalex-snapshot
Is methotrexate effective in ankylosing spondylitis?
inferredcites →https://doi.org/10.1093/rheumatology/keg358openalex-snapshot
Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1093/rheumatology/keh313openalex-snapshot
Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial
inferredcites →https://doi.org/10.1093/rheumatology/kel218openalex-snapshot
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study
inferredcites →https://doi.org/10.1093/rheumatology/kep122openalex-snapshot
Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1093/rheumatology/kep393openalex-snapshot
Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein
inferredcites →https://doi.org/10.1093/rheumatology/keq292openalex-snapshot
Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1093/rheumatology/kes019openalex-snapshot
Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO
inferredcites →https://doi.org/10.1093/rheumatology/ket310openalex-snapshot
Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1093/rheumatology/keu457openalex-snapshot
Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting
inferredcites →https://doi.org/10.1093/rheumatology/kev353openalex-snapshot
Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study
inferredcites →https://doi.org/10.1093/rheumatology/kev434openalex-snapshot
Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
inferredcites →https://doi.org/10.1097/bor.0000000000000254openalex-snapshot
Microtrauma
inferredcites →https://doi.org/10.1097/phm.0000000000000524openalex-snapshot
Effect of Electromyographic Biofeedback Training on Pain, Quadriceps Muscle Strength, and Functional Ability in Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1136/annrheumdis-2012-203046openalex-snapshot
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
inferredcites →https://doi.org/10.1136/annrheumdis-2013-204641openalex-snapshot
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register
inferredcites →https://doi.org/10.1136/annrheumdis-2014-205228openalex-snapshot
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration
inferredcites →https://doi.org/10.1136/annrheumdis-2014-205351openalex-snapshot
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
inferredcites →https://doi.org/10.1136/annrheumdis-2016-210025openalex-snapshot
Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases
inferredcites →https://doi.org/10.1136/annrheumdis-2016-210456openalex-snapshot
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
inferredcites →https://doi.org/10.1136/annrheumdis-annrheumdis-2014-206747openalex-snapshot
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)
inferredcites →https://doi.org/10.1136/ard.2006.054098openalex-snapshot
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial
inferredcites →https://doi.org/10.1136/ard.2006.064717openalex-snapshot
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment
inferredcites →https://doi.org/10.1136/ard.2007.087411openalex-snapshot
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
inferredcites →https://doi.org/10.1136/ard.2009.100354openalex-snapshot
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension
inferredcites →https://doi.org/10.1136/ard.2010.143347openalex-snapshot
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE–JIA): a multicentre randomised open-label clinical trial
inferredcites →https://doi.org/10.1136/ard.61.10.941openalex-snapshot
A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies
inferredcites →https://doi.org/10.1136/bmj.39489.470347.adopenalex-snapshot
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
inferredcites →https://doi.org/10.1136/bmj.a744openalex-snapshot
Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
inferredcites →https://doi.org/10.1186/1546-0096-12-29openalex-snapshot
Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry
inferredcites →https://doi.org/10.1186/ar4072openalex-snapshot
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
inferredcites →https://doi.org/10.1186/s12969-016-0099-zopenalex-snapshot
Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration
inferredcites →https://doi.org/10.1186/s12969-016-0126-0openalex-snapshot
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
inferredcites →https://doi.org/10.1186/s12969-017-0138-4openalex-snapshot
A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study
inferredcites →https://doi.org/10.1186/s13075-016-1109-8openalex-snapshot
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1186/s13075-016-1170-3openalex-snapshot
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
inferredcites →https://doi.org/10.3899/jrheum.081028openalex-snapshot
Health-Related Quality of Life, Physical Function, Fatigue, and Disease Activity in Children with Established Polyarticular Juvenile Idiopathic Arthritis
inferredcites →https://doi.org/10.3899/jrheum.140472openalex-snapshot
Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics
inferredcites →https://doi.org/10.3899/jrheum.150430openalex-snapshot
Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
inferredcites →https://doi.org/10.3899/jrheum.170251openalex-snapshot
Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis
inferredcites →https://doi.org/10.5114/reum.2016.58757openalex-snapshot
Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4048931openalex-extracted
Adalimumab Superior to Etanercept as First Line Biologic in ERA- a Drug Survival Single Centre Study Spanning 10 Years
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.8330openalex-snapshot
Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/14651858.cd014961openalex-snapshot
Dose reduction and discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1002/acr.23871openalex-snapshot
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
inferred← citeshttps://doi.org/10.1002/acr.24192openalex-snapshot
Outcome Measures for Juvenile Idiopathic Arthritis Disease Activity
inferred← citeshttps://doi.org/10.1002/acr.24206openalex-snapshot
Variability in Interpretation of Magnetic Resonance Imaging of the Pediatric Sacroiliac Joint
inferred← citeshttps://doi.org/10.1002/acr.24529openalex-snapshot
Children With Enthesitis‐Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis
inferred← citeshttps://doi.org/10.1002/acr.24537openalex-snapshot
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA–B27, and Equal Sex Representation in Sacroiliitis
inferred← citeshttps://doi.org/10.1002/acr.24727openalex-snapshot
Effectiveness and Safety of High‐Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance
inferred← citeshttps://doi.org/10.1002/acr.24759openalex-snapshot
Musculoskeletal Ultrasound in Childhood Arthritis Limited Examination: A Comprehensive, Reliable, Time‐Efficient Assessment of Synovitis
inferred← citeshttps://doi.org/10.1002/acr.24839openalex-snapshot
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging
inferred← citeshttps://doi.org/10.1002/acr.24853openalex-snapshot
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/acr.24857openalex-snapshot
Changing Patterns in Treatment, Remission Status, and Categories in a Long‐Term Nordic Cohort Study of Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/acr.24859openalex-snapshot
Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study
inferred← citeshttps://doi.org/10.1002/acr.24989openalex-snapshot
Patient‐Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two‐Year Results From an International Phase III Study
inferred← citeshttps://doi.org/10.1002/acr.25156openalex-snapshot
Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept
inferred← citeshttps://doi.org/10.1002/acr.25339openalex-snapshot
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/acr.25417openalex-snapshot
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/acr.25482openalex-snapshot
25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges
inferred← citeshttps://doi.org/10.1002/acr.25565openalex-snapshot
Core Set of Responsive and Discriminatory Measures for Use in Pragmatic Trials of Youth With Axial Juvenile Spondyloarthritis
inferred← citeshttps://doi.org/10.1002/acr.80111openalex-snapshot
From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis
inferred← citeshttps://doi.org/10.1002/acr2.11353openalex-snapshot
Determinants of Tumor Necrosis Factor Inhibitor Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes
inferred← citeshttps://doi.org/10.1002/acr2.11444openalex-snapshot
Association Between Patient‐Reported Outcomes and Treatment Failure in Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/acr2.11485openalex-snapshot
Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
inferred← citeshttps://doi.org/10.1002/acr2.11701openalex-snapshot
Predictors of Disease Activity in Patients With Juvenile Idiopathic Arthritis at 12 and 24 Months After Diagnosis
inferred← citeshttps://doi.org/10.1002/art.41234openalex-snapshot
The Patient and Parent Perspective on Methotrexate in Recent Juvenile Idiopathic Arthritis Guidelines: Comment on the Article by Ringold et al
inferred← citeshttps://doi.org/10.1002/art.41390openalex-snapshot
New Medications Are Needed for Children With Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/art.41455openalex-snapshot
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1
inferred← citeshttps://doi.org/10.1002/art.41772openalex-snapshot
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2
inferred← citeshttps://doi.org/10.1002/art.41912openalex-snapshot
“To Randomize, or Not to Randomize, That is the Question”
inferred← citeshttps://doi.org/10.1002/art.42036openalex-snapshot
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging
inferred← citeshttps://doi.org/10.1002/art.42037openalex-snapshot
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1002/art.42481openalex-snapshot
Incidence of Orofacial Manifestations of Juvenile Idiopathic Arthritis From Diagnosis to Adult Care Transition: A Population‐Based Cohort Study
inferred← citeshttps://doi.org/10.1002/art.43041openalex-snapshot
Trends in New Use of Disease‐Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022
inferred← citeshttps://doi.org/10.1002/art.70050openalex-snapshot
Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease
inferred← citeshttps://doi.org/10.1002/bdr2.2221openalex-snapshot
Leflunomide exposure through second trimester of pregnancy: A case report
inferred← citeshttps://doi.org/10.1002/cpt.3441openalex-snapshot
Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient Data
inferred← citeshttps://doi.org/10.1002/pds.5803openalex-snapshot
Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1002/pds.70412openalex-snapshot
Uptake and Use of Biologic Therapies in Paediatric Immune‐Mediated Inflammatory Diseases: An Australian Population‐Based Study
inferred← citeshttps://doi.org/10.1002/ppul.26681openalex-snapshot
Methotrexate does not affect lung function in children with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1002/psp4.13104openalex-snapshot
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/978-3-030-65574-7_31openalex-snapshot
Restless Legs Syndrome and Periodic Leg Movements of Sleep
inferred← citeshttps://doi.org/10.1007/978-3-030-90642-9_12openalex-snapshot
Care of the Child with a Possible Rheumatological Disorder
inferred← citeshttps://doi.org/10.1007/978-3-031-23488-0_4openalex-snapshot
Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/978-3-031-23488-0_6openalex-snapshot
Juvenile Spondyloarthritis
inferred← citeshttps://doi.org/10.1007/978-3-031-54281-7_34openalex-snapshot
Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/978-3-032-13116-4_22openalex-snapshot
Comorbidity Patterns Before and After Juvenile Idiopathic Arthritis Diagnosis
inferred← citeshttps://doi.org/10.1007/978-3-662-60411-3_23-1openalex-snapshot
Gelenkpunktionen in der pädiatrischen Rheumatologie
inferred← citeshttps://doi.org/10.1007/978-3-662-60980-4_73openalex-snapshot
Arthritiden
inferred← citeshttps://doi.org/10.1007/978-3-662-61937-7_73-1openalex-snapshot
Arthritiden – Begutachtung
inferred← citeshttps://doi.org/10.1007/s00264-024-06175-8openalex-snapshot
Total hip arthroplasty in adolescents: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00296-019-04385-7openalex-snapshot
Leflunomide treatment in juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s00296-020-04581-wopenalex-snapshot
Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics
inferred← citeshttps://doi.org/10.1007/s00296-020-04596-3openalex-snapshot
Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study
inferred← citeshttps://doi.org/10.1007/s00296-021-04854-yopenalex-snapshot
Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience
inferred← citeshttps://doi.org/10.1007/s00296-021-04890-8openalex-snapshot
Spinal involvement in juvenile idiopathic arthritis: what do we miss without imaging?
inferred← citeshttps://doi.org/10.1007/s00296-021-05077-xopenalex-snapshot
Non-disease specific patient-reported outcome measures of health-related quality of life in juvenile idiopathic arthritis: a systematic review of current research and practice
inferred← citeshttps://doi.org/10.1007/s00296-021-05083-zopenalex-snapshot
Coincidence of juvenile idiopathic arthritis and type 1 diabetes: a case-based review
inferred← citeshttps://doi.org/10.1007/s00296-023-05274-wopenalex-snapshot
Recent updates in enthesitis-related arthritis
inferred← citeshttps://doi.org/10.1007/s00296-023-05293-7openalex-snapshot
Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study
inferred← citeshttps://doi.org/10.1007/s00296-023-05297-3openalex-snapshot
The role of liver transaminase levels in methotrexate intolerance in juvenile idiopathic arthritis—a cross-sectional study
inferred← citeshttps://doi.org/10.1007/s00296-024-05750-xopenalex-snapshot
New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review
inferred← citeshttps://doi.org/10.1007/s00393-021-01114-zopenalex-snapshot
Polyartikuläre juvenile idiopathische Arthritis und rheumatoide Arthritis
inferred← citeshttps://doi.org/10.1007/s00431-023-05367-5openalex-snapshot
Assessment of quality of life and physical activity in patients with oligoarticular juvenile idiopathic arthritis in remission
inferred← citeshttps://doi.org/10.1007/s00431-025-06084-xopenalex-snapshot
The impact of BMI on disease activity and growth outcomes in juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s00431-025-06495-wopenalex-snapshot
Real-life data on treatment strategies for polyarticular juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s10067-020-05520-7openalex-snapshot
Outcomes and predictors of juvenile idiopathic arthritis in Southeast Asia: a Singapore longitudinal study over a decade
inferred← citeshttps://doi.org/10.1007/s10067-021-06013-xopenalex-snapshot
Comment on “Hip involvement in children with enthesitis-related arthritis (ERA) is associated with poor outcomes in adulthood”
inferred← citeshttps://doi.org/10.1007/s10067-021-06021-xopenalex-snapshot
In response to comment on “Hip involvement in children with enthesitis-related arthritis (ERA) is associated with poor outcomes in adulthood” by Ferjani H L et al.
inferred← citeshttps://doi.org/10.1007/s10067-022-06095-1openalex-snapshot
Retrospective study of 98 patients with X-linked agammaglobulinemia complicated with arthritis
inferred← citeshttps://doi.org/10.1007/s10067-023-06569-wopenalex-snapshot
Outcomes of intraarticular triamcinolone acetonide injection in children with non-systemic juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s10067-023-06835-xopenalex-snapshot
Use of transient elastography to assess hepatic steatosis and fibrosis in patients with juvenile idiopathic arthritis during methotrexate treatment
inferred← citeshttps://doi.org/10.1007/s10067-024-06867-xopenalex-snapshot
The Saudi consensus recommendations for the management of psoriatic arthritis (2023)
inferred← citeshttps://doi.org/10.1007/s10067-024-06928-1openalex-snapshot
Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?
inferred← citeshttps://doi.org/10.1007/s10067-024-07012-4openalex-snapshot
Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs
inferred← citeshttps://doi.org/10.1007/s10067-025-07308-zopenalex-snapshot
Fertility, pregnancy outcomes, and disease activity during pregnancy in patients with juvenile idiopathic arthritis: a descriptive study
inferred← citeshttps://doi.org/10.1007/s10067-025-07334-xopenalex-snapshot
Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis
inferred← citeshttps://doi.org/10.1007/s10067-025-07340-zopenalex-snapshot
Evaluation of ILAR and PRINTO classifications for juvenile idiopathic arthritis: oligoarticular JIA vs early-onset ANA-positive JIA
inferred← citeshttps://doi.org/10.1007/s10067-025-07792-3openalex-snapshot
PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s10787-025-01664-7openalex-snapshot
Pharmacological modes of plant-derived compounds for targeting inflammation in rheumatoid arthritis: A comprehensive review on immunomodulatory perspective
inferred← citeshttps://doi.org/10.1007/s11926-021-01036-4openalex-snapshot
Advances in Juvenile Spondyloarthritis
inferred← citeshttps://doi.org/10.1007/s11926-023-01112-xopenalex-snapshot
Treat-to-Target in Pediatric Rheumatic Diseases
inferred← citeshttps://doi.org/10.1007/s11926-024-01170-9openalex-snapshot
Updating the 2019 ACR/SAA/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (SPARTAN 2024 Annual Meeting Proceedings)
inferred← citeshttps://doi.org/10.1007/s12020-023-03600-7openalex-snapshot
Thyroid function in pediatric patients with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s12098-023-04939-5openalex-snapshot
Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s12519-022-00530-8openalex-snapshot
Research progress in drug therapy of juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s12668-026-02882-1openalex-snapshot
The Effect of Zingerone-Loaded Hyaluosomes Against Rheumatoid Arthritis: In Vivo Study
inferred← citeshttps://doi.org/10.1007/s13312-021-2155-0openalex-snapshot
Comparative Efficacy and Safety of Non-Steroidal Anti-Inflammatory Drugs in Patients With Juvenile Idiopathic Arthritis: A Systematic Review and Network Meta-analysis
inferred← citeshttps://doi.org/10.1007/s13760-020-01572-3openalex-snapshot
Coexistence of Becker muscular dystrophy and HLA-B27 positive spondyloarthritis
inferred← citeshttps://doi.org/10.1007/s40267-026-01241-0openalex-snapshot
Differences in time to drug initiation and inactive disease achievement by insurance type in patients with nonsystemic juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1007/s40271-020-00458-zopenalex-snapshot
Development and Acceptability of a Patient Decision Aid for Pain Management in Juvenile Idiopathic Arthritis: The JIA Option Map
inferred← citeshttps://doi.org/10.1007/s40272-019-00354-6openalex-snapshot
Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis
inferred← citeshttps://doi.org/10.1007/s40272-020-00416-0openalex-snapshot
Treatment of Juvenile Spondyloarthritis: Where We Stand
inferred← citeshttps://doi.org/10.1007/s40272-020-00422-2openalex-snapshot
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s40272-021-00436-4openalex-snapshot
Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s40272-021-00447-1openalex-snapshot
Correction to: Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s40272-022-00496-0openalex-snapshot
Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s40272-023-00618-2openalex-snapshot
Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs
inferred← citeshttps://doi.org/10.1007/s40272-024-00643-9openalex-snapshot
Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management
inferred← citeshttps://doi.org/10.1007/s40272-025-00720-7openalex-snapshot
Navigating the Biosimilars from Bench to Bedside in Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s40272-025-00725-2openalex-snapshot
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data
inferred← citeshttps://doi.org/10.1007/s40272-025-00735-0openalex-snapshot
Toward Optimal Treatment Outcomes in New-Onset Polyarticular-Course Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1007/s40744-026-00869-8openalex-snapshot
Comparison of Systemic Corticosteroid Therapy Practices Between Pediatric and Adult Rheumatologists: A Multicenter Survey Study
inferred← citeshttps://doi.org/10.1016/b978-0-443-11980-4.00012-xopenalex-snapshot
Therapeutics: Nonbiologics
inferred← citeshttps://doi.org/10.1016/b978-0-443-11980-4.00014-3openalex-snapshot
Physical and Occupational Therapy
inferred← citeshttps://doi.org/10.1016/b978-0-443-11980-4.00018-0openalex-snapshot
Polyarticular Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1016/j.ajo.2022.11.010openalex-snapshot
Comparison of Uveitis Incidence by Medication in Juvenile Idiopathic Arthritis and Implications for Screening
inferred← citeshttps://doi.org/10.1016/j.ard.2026.03.030openalex-snapshot
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1016/j.berh.2024.101983openalex-snapshot
The inequity of global healthcare in pediatric rheumatology
inferred← citeshttps://doi.org/10.1016/j.berh.2025.102069openalex-snapshot
New developments in ultrasound and MRI imaging of pediatric rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115254openalex-snapshot
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients – Lessons learned from the COVID-19 pandemic
inferred← citeshttps://doi.org/10.1016/j.clim.2022.109018openalex-snapshot
TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study
inferred← citeshttps://doi.org/10.1016/j.clim.2022.109143openalex-snapshot
Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary care
inferred← citeshttps://doi.org/10.1016/j.coi.2026.102840openalex-snapshot
Towards personalized treatment in juvenile idiopathic arthritis: moving beyond the trial-and-error strategy
inferred← citeshttps://doi.org/10.1016/j.coph.2022.102226openalex-snapshot
Therapeutic strategies for treating juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1016/j.cpha.2020.09.003openalex-snapshot
Overview of Pediatric Rheumatology
inferred← citeshttps://doi.org/10.1016/j.cpha.2020.09.004openalex-snapshot
Overview of Pediatric Rheumatology
inferred← citeshttps://doi.org/10.1016/j.ctcp.2022.101618openalex-snapshot
Effects of neural mobilization in disorders associated with chronic secondary musculoskeletal pain: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ejr.2020.02.005openalex-snapshot
Serum, synovial and mRNA expression of interleukin-33 in juvenile idiopathic arthritis patients: Potential role as a marker of disease activity and relation to musculoskeletal ultrasound
inferred← citeshttps://doi.org/10.1016/j.ero.2025.11.010openalex-snapshot
Canakinumab for systemic-onset juvenile idiopathic arthritis/Still’s disease—effectiveness and safety data from the BiKeR registry
inferred← citeshttps://doi.org/10.1016/j.ijom.2024.06.001openalex-snapshot
Long-term follow-up of corrective jaw surgery including distraction osteogenesis in 32 patients with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.107917openalex-snapshot
Infliximab and tocilizumab reduce anxiety-like behavior, improve cognitive performance and reverse neuropathological alterations in juvenile rats with severe autoimmune arthritis
inferred← citeshttps://doi.org/10.1016/j.jbspin.2021.105151openalex-snapshot
Therapeutic alliance is associated to treatment adherence in children with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1016/j.jmii.2025.05.011openalex-snapshot
Taiwan guideline for the diagnosis and management of juvenile idiopathic arthritis: Consensus statement of the Taiwan Academy of Pediatric Allergy, Asthma and Immunology
inferred← citeshttps://doi.org/10.1016/j.med.2025.05.004openalex-snapshot
Artritis idiopática juvenil
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.107843openalex-snapshot
Trend in the use of biological drugs in pediatric patients with immune-mediated inflammatory diseases: Insight from the large-scale Italian VALORE project
inferred← citeshttps://doi.org/10.1016/j.rbmo.2021.03.018openalex-snapshot
Association between arthritis treatments and ovarian reserve: a prospective study
inferred← citeshttps://doi.org/10.1016/j.rcreu.2023.08.006openalex-snapshot
Growing up with juvenile idiopathic arthritis: Social issues
inferred← citeshttps://doi.org/10.1016/j.rcreue.2023.08.003openalex-snapshot
Growing up with juvenile idiopathic arthritis: Social issues
inferred← citeshttps://doi.org/10.1016/j.rdc.2021.07.001openalex-snapshot
Recent Updates in Juvenile Spondyloarthritis
inferred← citeshttps://doi.org/10.1016/j.rdc.2021.07.009openalex-snapshot
Juvenile Idiopathic Arthritis Treatment Updates
inferred← citeshttps://doi.org/10.1016/j.rdc.2021.07.012openalex-snapshot
Pharmacosurveillance in Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1016/j.rdc.2021.08.006openalex-snapshot
Implementation Science in Pediatric Rheumatology: A Path to Health Equity
inferred← citeshttps://doi.org/10.1016/j.rdc.2022.03.007openalex-snapshot
Treatment Guidelines in Pediatric Rheumatic Diseases
inferred← citeshttps://doi.org/10.1016/j.rdc.2022.05.002openalex-snapshot
The Meaningful Role of Patients, and Other Stakeholders in Clinical Practice Guideline Development
inferred← citeshttps://doi.org/10.1016/j.rdc.2025.05.002openalex-snapshot
The Challenges of New Biologic Therapies in Pediatrics
inferred← citeshttps://doi.org/10.1016/j.rhum.2021.09.006openalex-snapshot
L’alliance thérapeutique est associée à l’adhésion au traitement chez les enfants atteints d’arthrite juvénile idiopathique
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2022.152038openalex-snapshot
Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA) - a drug-survival single centre study spanning 10 years
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2025.152774openalex-snapshot
The effectiveness and safety of rituximab in juvenile idiopathic arthritis: Hints from the ITHACA monocentric registry
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2026.152956openalex-snapshot
Evaluation of disease severity and treatment responses in patients with enthesitis-related arthritis
inferred← citeshttps://doi.org/10.1016/j.vhri.2026.101601openalex-snapshot
Cost-Utility and Budget Impact Analysis of Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Refractory Nonsystemic Juvenile Idiopathic Arthritis in Thailand
inferred← citeshttps://doi.org/10.1016/j.yapd.2021.05.014openalex-snapshot
Updates in Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1016/s2352-4642(19)30188-9openalex-snapshot
Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions
inferred← citeshttps://doi.org/10.1016/s2665-9913(20)30025-4openalex-snapshot
Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study
inferred← citeshttps://doi.org/10.1016/s2665-9913(20)30058-8openalex-snapshot
Evaluating the past might enlighten the future
inferred← citeshttps://doi.org/10.1016/s2665-9913(20)30426-4openalex-snapshot
Advancing the treatment of juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1016/s2665-9913(21)00252-6openalex-snapshot
Precision medicine in juvenile idiopathic arthritis—has the time arrived?
inferred← citeshttps://doi.org/10.1016/s2665-9913(24)00127-9openalex-snapshot
Biosimilars in childhood chronic rheumatic diseases: friend or foe?
inferred← citeshttps://doi.org/10.1038/s41390-022-02288-1openalex-snapshot
Association between Interleukin-17F 7488A/G and 7383A/G polymorphisms and susceptibility to juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1038/s41390-023-02637-8openalex-snapshot
The plasma levels of Dickkopf-1 elevated in patients with Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1038/s41572-021-00293-yopenalex-snapshot
Psoriatic arthritis
inferred← citeshttps://doi.org/10.1038/s41572-021-00332-8openalex-snapshot
Juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1038/s41584-024-01079-8openalex-snapshot
Treatment of non-systemic juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1038/s41598-020-64852-1openalex-snapshot
A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency
inferred← citeshttps://doi.org/10.1038/s41598-023-36308-9openalex-snapshot
Characteristics of persistent arthritis with refractory Kawasaki disease: a single-center retrospective study
inferred← citeshttps://doi.org/10.1055/a-2403-6334openalex-snapshot
Anti-Drug-Antikörper und der Einfluss von Methotrexat und Biologika-Applikationsintervall
inferred← citeshttps://doi.org/10.1055/a-2716-0588openalex-snapshot
Anti-Drug-Antikörper und der Einfluss von Methotrexat und Biologika-Applikationsintervall
inferred← citeshttps://doi.org/10.1056/nejmra2402073openalex-snapshot
Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1080/00325481.2024.2325333openalex-snapshot
Adverse events of biological agents in pediatric rheumatologic diseases
inferred← citeshttps://doi.org/10.1080/08923973.2024.2421523openalex-snapshot
Efficacy and safety of ibuprofen and naproxen in the treatment of oligoarticular juvenile idiopathic arthritis: bi-national cohort study
inferred← citeshttps://doi.org/10.1080/08923973.2026.2657954openalex-snapshot
Promising efficacy of coenzyme Q10 supplementation as adjunctive therapy in juvenile idiopathic arthritis: a randomized-controlled pilot study
inferred← citeshttps://doi.org/10.1080/09273948.2026.2651789openalex-snapshot
Familial Granulomatous Uveitis with Arthritis Suggestive of Blau Syndrome: A Multigenerational Case Series from India
inferred← citeshttps://doi.org/10.1080/09638288.2024.2367602openalex-snapshot
Meaningful contributions of rehabilitation for people with persistent pain; a reflexive thematic analysis
inferred← citeshttps://doi.org/10.1080/10837450.2023.2289170openalex-snapshot
Emulgels: a promising topical drug delivery system for arthritis management and care
inferred← citeshttps://doi.org/10.1080/14656566.2020.1796970openalex-snapshot
Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies
inferred← citeshttps://doi.org/10.1080/14712598.2020.1733524openalex-snapshot
Current and emerging biologics for the treatment of juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1080/14712598.2022.2105140openalex-snapshot
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia
inferred← citeshttps://doi.org/10.1080/14712598.2022.2123703openalex-snapshot
Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases
inferred← citeshttps://doi.org/10.1080/14712598.2026.2635527openalex-snapshot
Biologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study
inferred← citeshttps://doi.org/10.1093/jpepsy/jsad048openalex-snapshot
Pain-Related Stigma and Its Associations With Clinical and Experimental Pain Severity in Youth With Chronic Musculoskeletal Pain Conditions
inferred← citeshttps://doi.org/10.1093/mr/road093openalex-snapshot
The effect of intra-articular steroid injection on the cartilage and tendon thicknesses in juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1093/mr/road101openalex-snapshot
The importance of small joint involvement in oligoarticular juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1093/mr/roae016openalex-snapshot
Evaluation of medication withdrawal in patients with non-systemic juvenile idiopathic arthritis in Japan using a web-based survey
inferred← citeshttps://doi.org/10.1093/mr/roaf035openalex-snapshot
Comparative clinical practice of juvenile idiopathic arthritis and rheumatoid arthritis in adolescents and young adults: A retrospective cohort study using Japanese health insurance claims data (2016–20)
inferred← citeshttps://doi.org/10.1093/mr/roaf042openalex-snapshot
Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or…
inferred← citeshttps://doi.org/10.1093/rap/rkag052openalex-snapshot
Holistic management of juvenile idiopathic arthritis across all ages: British Society for Rheumatology Guideline scope
inferred← citeshttps://doi.org/10.1093/rheumatology/keaa877openalex-snapshot
Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA
inferred← citeshttps://doi.org/10.1093/rheumatology/keab812openalex-snapshot
Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry
inferred← citeshttps://doi.org/10.1093/rheumatology/keab914openalex-snapshot
Efficacy of pulse dexamethasone in non-systemic juvenile idiopathic arthritis: a double-blind randomized controlled trial
inferred← citeshttps://doi.org/10.1093/rheumatology/keac617openalex-snapshot
CCL24, CXCL9 and CXCL10 are increased in synovial fluid in patients with juvenile idiopathic arthritis requiring advanced treatment
inferred← citeshttps://doi.org/10.1093/rheumatology/kead490openalex-snapshot
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis
inferred← citeshttps://doi.org/10.1093/rheumatology/keae025openalex-snapshot
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry
inferred← citeshttps://doi.org/10.1093/rheumatology/keae039openalex-snapshot
Detection of inflammation by whole-body MRI in young people with juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1093/rheumatology/keae148openalex-snapshot
Comment on: Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure
inferred← citeshttps://doi.org/10.1093/rheumatology/keae180openalex-snapshot
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1093/rheumatology/keag186openalex-snapshot
TAK1 inhibition restores p53 expression and suppresses inflammation and hyperplasia in JIA synovial fibroblasts
inferred← citeshttps://doi.org/10.1097/bor.0000000000000727openalex-snapshot
Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?
inferred← citeshttps://doi.org/10.1097/bor.0000000000000948openalex-snapshot
When to stop medication in juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1097/bor.0000000000000950openalex-snapshot
Challenges in treating juvenile idiopathic arthritis
inferred← citeshttps://doi.org/10.1097/bor.0000000000001016openalex-snapshot
Drug therapy in juvenile spondyloarthritis
inferred← citeshttps://doi.org/10.1097/fpc.0000000000000622openalex-snapshot
Genetic variation in SLCO1B1 is associated with methotrexate intolerance symptoms in juvenile idiopathic arthritis patients
inferred← citeshttps://doi.org/10.1097/ms9.0000000000003011openalex-snapshot
Evaluating subclinical atherosclerosis, arterial stiffness, and lipid profile in patients with anti neutrophilic cytoplasmic antibodies associated vasculitis: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1097/rhu.0000000000001406openalex-snapshot
Role of Serum MRP8/14 in Predicting Response to Methotrexate in Children With Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1097/rhu.0000000000001955openalex-snapshot
Childhood-Onset Sacroiliitis
inferred← citeshttps://doi.org/10.1097/rhu.0000000000002001openalex-snapshot
The Juvenile Spondyloarthritis Disease Activity Index Is a Useful Tool in Enthesitis-Related Arthritis
inferred← citeshttps://doi.org/10.1097/rhu.0000000000002032openalex-snapshot
Can Whole-Body Magnetic Resonance Imaging Predict Relapse in Juvenile Idiopathic Arthritis? A Longitudinal Pilot Study
inferred← citeshttps://doi.org/10.1097/rhu.0000000000002240openalex-snapshot
The Number of Affected Joints Is Still a Distinguishing Criterion for Classifying Patients With Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1097/rhu.0000000000002254openalex-snapshot
Global Guidelines for Psoriatic Arthritis Management
inferred← citeshttps://doi.org/10.1097/rhu.0000000000002341openalex-snapshot
Assessment of Subclinical Atherosclerosis Markers and Their Relationship With Disease Activity in Juvenile Idiopathic Arthritis
inferred← citeshttps://doi.org/10.1097/rhu.0000000000002353openalex-snapshot
Impact of Health Care Financing Models on Biological Agent Accessibility and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Comparative Study From Türkiye and India
showing the first 200 of 460 · page through all 460
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.